In the last 10 years, psychedelic drugs like LSD, magic mushrooms, DMT, a host of plant medicines" " including ayahuasca, iboga, salvia, peyote " and related compounds like MDMA and ketamine have begun to lose much of their 1960s-driven stigma. Promising clinical trials suggest that psychedelics may prove game-changing treatments for depression, PTSD and addiction. The response from the psychiatric community ... has been largely open-armed. The drugs may well mark the field's first paradigm shift since SSRIs in the 1980s. In 2017, for example, the US Food and Drug Administration designated MDMA a "breakthrough therapy", which meant it would be fast-tracked through to the second stage of Phase-3 trials. Psychedelics remain Schedule-1 drugs federally in the US and Class-A in the UK, but rules are relaxing. This wave of psychedelic enthusiasm in psychiatry isn't the first. They were originally heralded as wonder drugs in the 1950s. Across some 6,000 studies on over 40,000 patients, psychedelics were tried as experimental treatments for an extraordinary range of conditions: alcoholism, depression, schizophrenia, criminal recidivism, childhood autism. And the results were promising. From as little as a single LSD session, studies suggested that the drug relieved problem drinking for 59% of alcoholic participants. Experimenting with lower, so-called "psycholytic" doses, many therapists were amazed by LSD's power as an adjunct to talking therapy.